Spots Global Cancer Trial Database for tumour
Every month we try and update this database with for tumour cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours | NCT00697879 | Solid Tumor | CHR-3996 | 18 Years - | Chroma Therapeutics | |
| Open Label Prostate Cancer Study | NCT01162395 | Prostate Cancer | AZD3514 | 20 Years - 130 Years | AstraZeneca | |
| Evaluation of a Prototype Hand Held Hybrid Gamma Camera | NCT03920371 | Tumour | gamma camera im... | 18 Years - | University of Leicester | |
| Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours | NCT00475956 | Neoplasms | AZD2171 AZD0530 | 18 Years - | AstraZeneca | |
| Safety of IMRT Treatment With Inhomogeneous Dose in Patients With Relapsed High-grade Gliomas. | NCT04610229 | Glioblastoma Mu... Glioblastoma Glioblastoma, A... | Hypofractionati... | 18 Years - | Arcispedale Santa Maria Nuova-IRCCS | |
| Functional Outcomes of Knee Protheses for Malignant Tumours of Bone | NCT04650594 | Knee Disease Bone Cancer | MUTARS® modular... | 18 Years - | University Hospital, Lille | |
| The HeLiX (Hemorrhage During Liver Resection: traneXamic Acid) Trial | NCT02261415 | Cancer Tumour Surgery | Tranexamic acid... Normal saline | 18 Years - | Sunnybrook Health Sciences Centre | |
| Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma | NCT01473095 | Solid Tumor Malignant Lymph... Tumor | ARQ 092 | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer | NCT00035100 | Ovarian Neoplas... Peritoneal Neop... Fallopian Tube ... | epothilone b | 18 Years - | Novartis | |
| Study Assessing Safety and Tolerability of AZD8931 Alone or in Combination With Paclitaxel in Japanese Patients. | NCT01003158 | Neoplasms Metastatic Canc... Breast Cancer | AZD8931 Paclitaxel | 20 Years - | AstraZeneca | |
| EPO906 Therapy in Patients With Advanced Melanoma | NCT00035165 | Melanoma | epothilone b | 18 Years - 85 Years | Novartis | |
| EPO906 Therapy in Patients With Prostate Cancer | NCT00035113 | Prostatic Neopl... | epothilone b | 18 Years - 85 Years | Novartis | |
| Study Assessing Safety and Tolerability of AZD8931 Alone or in Combination With Paclitaxel in Japanese Patients. | NCT01003158 | Neoplasms Metastatic Canc... Breast Cancer | AZD8931 Paclitaxel | 20 Years - | AstraZeneca | |
| Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma | NCT01473095 | Solid Tumor Malignant Lymph... Tumor | ARQ 092 | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| EPO906 Therapy in Patients With Advanced Colorectal Cancer | NCT00035087 | Colorectal Neop... Colonic Neoplas... | epothilone b | 18 Years - 85 Years | Novartis | |
| Tranexamic Acid Versus Placebo for Blood to Reduce Perioperative Bleeding Post-liver Resection | NCT01651182 | Cancer Tumour Surgery | No tranexamic a... Tranexamic Acid | 18 Years - | Sunnybrook Health Sciences Centre | |
| Safety Study to Evaluate CHR-2797 in Patients With Advanced Tumours | NCT00692354 | Advanced Solid ... | CHR-2797 (tosed... | 18 Years - | Chroma Therapeutics | |
| To Compare the Clinical Application of 18F-LNC1007 Injection PET/CT and 18F-FDG PET/CT | NCT06205888 | Tumour | 18F-LNC1007（18F... | 18 Years - | Jinling Hospital, China | |
| EPO906 Therapy in Patients With Advanced Breast Cancer | NCT00035126 | Breast Neoplasm... | epothilone b | 18 Years - 85 Years | Novartis | |
| Reduced Intra-operative Blood Loss in Pancreaticoduodenectomy for Pancreatic or Peri-ampullary Tumors; Monocentric Trial on Standard Open Versus Minimally Invasive Surgery | NCT01712971 | Surgery Pancreatic Tumo... Peri-ampullary ... Blood Loss | 18 Years - 80 Years | University Hospital, Gasthuisberg | ||
| DCE CT/MRI Scanning Study in Patients With Solid Tumours (AstraZeneca and Royal Marsden Hospital Imaging Study) | NCT00748891 | Cancer | Recentin (Cedir... | 18 Years - | AstraZeneca | |
| EPO906 in Carcinoid and Other Neuroendocrine Tumors | NCT00050349 | Carcinoid Neuroendocrine ... | EPO906 epothilo... | 18 Years - | Novartis | |
| Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma | NCT00777153 | Recurrent Gliob... | Cediranib Cediranib Lomustine Chemo... Placebo Cediran... | 18 Years - 100 Years | AstraZeneca | |
| Effect of Food Upon Pharmacokinetics of Single Oral Dose of Cediranib (AZD2171, Recentin™) | NCT00306891 | Cancer | Cediranib Cediranib 30 - ... | 18 Years - | AstraZeneca | |
| EPO906 Therapy in Patients With Advanced Kidney Cancer | NCT00035243 | Kidney Neoplasm... | epothilone b | 18 Years - 85 Years | Novartis | |
| Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II) | NCT00900627 | Neoplasms Breast Neoplasm... Breast Cancer | AZD8931 Paclitaxel Placebo | 18 Years - 150 Years | AstraZeneca | |
| EPO906 Therapy in Patients With Prostate Cancer | NCT00035113 | Prostatic Neopl... | epothilone b | 18 Years - 85 Years | Novartis | |
| EPO906 in Carcinoid and Other Neuroendocrine Tumors | NCT00050349 | Carcinoid Neuroendocrine ... | EPO906 epothilo... | 18 Years - | Novartis | |
| Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer | NCT01151215 | Neoplasms Breast Neoplasm... Breast Cancer | AZD8931 anastrozole Placebo | 18 Years - | AstraZeneca | |
| Safety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours | NCT00697879 | Solid Tumor | CHR-3996 | 18 Years - | Chroma Therapeutics | |
| A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer. | NCT01602380 | Hormone Recepto... | faslodex 500mg arimidex 1mg faslodex dummy arimidex dummy | 18 Years - 130 Years | AstraZeneca | |
| Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors | NCT00395434 | Tumors | Combretastatin ... Bevacizumab (Av... | 18 Years - | Mateon Therapeutics | |
| A Post-Authorisation Safety Study Patient Registry of Patients With Neuroblastoma Being Treated With Dinutuximab Beta | NCT04253015 | Neuroblastoma | Data-collection | 1 Year - 18 Years | EusaPharma (UK) Limited | |
| Safety of IMRT Treatment With Inhomogeneous Dose in Patients With Relapsed High-grade Gliomas. | NCT04610229 | Glioblastoma Mu... Glioblastoma Glioblastoma, A... | Hypofractionati... | 18 Years - | Arcispedale Santa Maria Nuova-IRCCS | |
| The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST). | NCT00385203 | Gastrointestina... Soft Tissue Sar... | AZD2171 | 18 Years - | AstraZeneca | |
| EPO906 Therapy in Patients With Advanced Breast Cancer | NCT00035126 | Breast Neoplasm... | epothilone b | 18 Years - 85 Years | Novartis | |
| EPO906 Therapy in Patients With Advanced Kidney Cancer | NCT00035243 | Kidney Neoplasm... | epothilone b | 18 Years - 85 Years | Novartis | |
| Optical Detection of Malignancy During Percutaneous Interventions | NCT01730365 | Pulmonary Coin ... Colon Cancer Li... Breast Cancer | Core biopsy pro... | 18 Years - | Philips Healthcare | |
| Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations | NCT01752920 | Solid Tumor | Derazantinib lo... Derazantinib mi... Derazantinib hi... Derazantinib at... | 18 Years - | Basilea Pharmaceutica | |
| Open Label Prostate Cancer Study | NCT01162395 | Prostate Cancer | AZD3514 | 20 Years - 130 Years | AstraZeneca |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
